OncoMatch/Clinical Trials/NCT06762080
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Is NCT06762080 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Cadonilimab (AK104) and Pemetrexed (Alimta) for leptomeningeal metastasis.
Treatment: Cadonilimab (AK104) · Pemetrexed (Alimta) — Leptomeningeal metastasis, characterized by tumor cells infiltrating and proliferating in the subarachnoid space, represents a distinct pattern of central nervous system involvement and is a fatal complication of malignant tumors. This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) bispecific antibodies combined with pemetrexed in patients with leptomeningeal metastasis.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Leptomeningeal Metastasis; Cerebrospinal fluid cytopathology is positive.
Prior therapy
Cannot have received: small molecule targeted therapy (EGFR-TKI, ALK-TKI, Osimertinib, Lorlatinib)
Exception: previously administered drugs are allowed
new drugs effective against leptomeningeal metastases were used, excluding those previously administered. These primarily included small molecule targeted therapies, such as EGFR-TKI/ALK-TKI drugs like Osimertinib and Lorlatinib.
Lab requirements
Blood counts
wbc≥4000/mm3, plt≥100000/mm3
Kidney function
normal kidney function
Liver function
normal liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify